Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK) by Whyte, S et al.
HEDS Discussion Paper: Cost-effectiveness of G-CSFs for febrile neutropenia prophylaxis in 
non-Hodgkin’s lymphoma: Whyte et al 
 - 1 - 
 
 
 
 
 
 
HEDS Discussion Paper 11-02 
 
 
 
Disclaimer: 
This is a Discussion Paper produced and published by the Health Economics and 
Decision Science (HEDS) Section at the School of Health and Related Research 
(ScHARR), University of Sheffield.  HEDS Discussion Papers are intended to provide 
information and encourage discussion on a topic in advance of formal publication.  
They represent only the views of the authors, and do not necessarily reflect the 
views or approval of the sponsors. 
 
White Rose Repository URL for this paper: 
http://eprints.whiterose.ac.uk/42909/ 
 
Once a version of Discussion Paper content is published in a peer-reviewed journal, 
this typically supersedes the Discussion Paper and readers are invited to cite the 
published version in preference to the original version. 
 
Published paper 
None. 
 
White Rose Research Online 
eprints@whiterose.ac.uk 
 
 
 
 
 
 
 
 
HEDS Discussion Paper: Cost-effectiveness of G-CSFs for febrile neutropenia prophylaxis in 
non-Hodgkin’s lymphoma: Whyte et al 
 - 2 - 
 
 
HEDS Discussion Paper: Cost-effectiveness of G-CSFs for febrile neutropenia prophylaxis in 
non-Hodgkin’s lymphoma: Whyte et al 
 - 3 - 
 Cost-effectiveness of granulocyte colony-
stimulating factor prophylaxis for febrile 
neutropenia in patients with non-Hodgkin’s 
lymphoma in the United Kingdom (UK) 
 
 
Whyte S1, Cooper KL1, Stevenson MD1, Akehurst R1 
 
1. School of Health and Related Research, University of Sheffield, Sheffield S1 
4DA, UK 
 
 
* Correspondence to: Sophie Whyte, Health Economics and Decision Science, 
University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK 
Telephone: +44 (0)114 222 0859 
Fax: +44 (0)114 272 4095 
E-mail: sophie.whyte@sheffield.ac.uk 
 
 
 
 
 
HEDS Discussion Paper: Cost-effectiveness of G-CSFs for febrile neutropenia prophylaxis in 
non-Hodgkin’s lymphoma: Whyte et al 
 - 4 - 
Abstract 
 
Introduction: We report a cost-effectiveness evaluation of granulocyte colony-
stimulating factors (G-CSFs) for prevention of febrile neutropenia (FN) following 
chemotherapy for non-Hodgkin’s lymphoma (NHL) in the United Kingdom (UK). 
 
Methods: A mathematical model was constructed simulating the experience of 
patients with NHL undergoing chemotherapy. Three strategies were modelled: 
primary prophylaxis (G-CSFs administered in all cycles); secondary prophylaxis (G-
CSFs administered in all cycles following an FN event), and no G-CSF prophylaxis. 
Three G-CSFs were considered: filgrastim; lenograstim and pegfilgrastim. Costs were 
taken from UK databases and utility values from published sources with the base 
case analysis using list prices for G-CSFs and a willingness to pay (WTP) threshold of 
£20,000 per QALY gained. A systematic review provided data on G-CSF efficacy. 
Probabilistic sensitivity analyses examined the effects of uncertainty in model 
parameters. 
 
Results: In the base-case analysis the most cost-effective strategy was primary 
prophylaxis with pegfilgrastim for a patient with baseline FN risk greater than 22%, 
secondary prophylaxis with pegfilgrastim for baseline FN risk 8-22%, and no G-CSFs 
for baseline FN risk less than 8%. Using a WTP threshold of £30,000, primary 
prophylaxis with pegfilgrastim was cost-effective for baseline FN risks greater than 
16%. In all analyses, pegfilgrastim dominated filgrastim and lenograstim. Sensitivity 
analyses demonstrated that higher WTP threshold, younger age, or reduced G-CSF 
prices result in G-CSF prophylaxis being cost-effective at lower baseline FN risk levels. 
 
Conclusions: Pegfilgrastim was the most cost-effective G-CSF. The most cost-effective 
strategy (primary or secondary prophylaxis) was dependent on underlying FN risk 
level, patient age, and G-CSF price. 
 
Key words: Cost-effectiveness; economic model; febrile neutropenia; granulocyte 
colony–stimulating factors; prophylaxis; non-Hodgkin’s lymphoma. 
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INTRODUCTION 
 
Neutropenia is the major dose-limiting toxicity of many chemotherapy regimens. 
Febrile neutropenia (FN) and its consequences are associated with substantial 
morbidity, mortality, and costs.(1) Chemotherapy-induced neutropenia and FN are 
also associated with dose reductions and delays to chemotherapy that may 
compromise patient survival.(2) In the UK the National Confidential Enquiry into 
Patient Outcome and Death performed a review of the care of patients who died 
within 30 days of receiving systemic anti-cancer therapy (SACT). (3) They report that 
the most commonly reported grade 3-4 toxicities associated with patients dying 
within 30 days of chemotherapy were neutropenia, neutropenic sepsis and infection. 
 
Recombinant human granulocyte colony-stimulating factors (G-CSFs) stimulate 
production of mature, functional neutrophils (4) which reduce the duration and 
severity of neutropenia and the incidence of FN when used as prophylaxis alongside 
chemotherapy.(5;6) G-CSF prophylaxis may be beneficial during treatment for many 
different cancers, depending on the risk of FN which is related to both chemotherapy 
regimen and patient risk factors.(7) This analysis focuses on non-Hodgkin’s 
lymphoma (NHL) as the evidence base for G-CSF prophylaxis is well developed in this 
setting. Three G-CSFs were in use at the time of this analysis: filgrastim, 
pegfilgrastim, and lenograstim. Pegfilgrastim is given as a single injection per 
chemotherapy cycle. Filgrastim and lenograstim prophylaxis both involve 
administration of a number of daily injections per cycle. It is recommended that 
filgrastim and lenograstim are given daily until the neutrophil count returns to the 
normal range (for up to 14 days per cycle for filgrastim, or up to 28 days for 
lenograstim). (8;9) 
 
G-CSFs can be administered as primary prophylaxis (in all cycles) or as secondary 
prophylaxis (in all remaining cycles following an episode of FN).  In the UK, patients 
receiving chemotherapy for NHL often receive secondary G-CSF prophylaxis.(10) 
Clinical guidelines on the use of G-CSFs have been produced by the European 
Organisation for Research and Treatment of Cancer (EORTC)(7) and also in the US by 
the American Society of Clinical Oncology (ASCO)(11) and the National 
Comprehensive Cancer Network (NCCN) (12). All sets of guidelines recommend that 
prophylactic G-CSFs should be used where the risk of FN associated with the 
chemotherapy regimen is greater than or equal to 20%, and may be considered 
where the risk is 10-20%, particularly where additional patient risk factors are 
present. 
 
The objective of this study is to model the cost-effectiveness of G-CSF prophylaxis of 
FN in patients with NHL compared with no use of G-CSF prophylaxis during 
treatment.  This follows on from a study of the cost-effectiveness of G-CSF 
prophylaxis of FN in patients with breast cancer.(13) In the analyses seven 
prophylaxis strategies are evaluated: primary prophylaxis and secondary prophylaxis 
for each of three G-CSFs (pegfilgrastim, filgrastim and lenograstim) and no G-CSF 
prophylaxis.  
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This study focuses on high-grade (aggressive) NHL for which most patients undergo 
chemotherapy treatment(14). The majority of randomised controlled trials (RCTs) of 
G-CSF prophylaxis for NHL relate to patients receiving intravenous chemotherapy for 
high-grade disease.(15) Data reported by the Office of National Statistics data for 
England in 2004 reported that out of 5172 cases of NHL which could be identified as 
either high-grade or low-grade approximately 72% were high-grade.(16) Using UK 
incidence data the mean age of NHL patients (both low grade and high grade) was 
calculated to be 65 years for men and 68 years for women.(17) 
 
 
METHODS 
 
Model structure 
 
A mathematical model was constructed using TreeAge Software (TreeAge Software 
Inc, USA) to estimate the costs and quality adjusted life years (QALYs) accrued by 
different strategies of G-CSF use. A lifetime horizon was used as an FN episode may 
impact on patient survival.  
 
The modelling approach conforms to the National Institute for Health and Clinical 
Excellence (NICE) methods guidance.(18) The model takes the perspective of the UK 
National Health Service (NHS) and was populated with UK data where possible. A 
meta-analysis was performed to obtain pooled estimates of effectiveness, EQ-5D 
utility values were used, and future costs and benefits were discounted at a rate of 
3.5% per annum. Willingness-to-pay (WTP) thresholds of £20,000 and £30,000 were 
used to calculate net monetary benefit (NMB).(18) The base case analysis is for 
females with the effect of gender examined in a scenario analysis. Several FN risk 
factors and NHL survival risk factors are included in the modelling and the 
relationships modelled are shown in Figure 1, and discussed below. 
 
The model structure is shown in Figure 2. For NHL, 6-8 cycles of chemotherapy are 
usually given.(14) A typical course of CHOP or R-CHOP (CHOP plus rituximab) 
chemotherapy for NHL in the UK is 6 cycles of 3 weeks each, or 18 weeks in total.(14) 
Recent studies have shown improvements in both complete remission and survival 
following reduction of the cycle length of standard 21 day CHOP (CHOP-21) to 14 
days (CHOP-14). (19) It is common that primary G-CSFs are administered in 
combination with CHOP-14. A regimen consisting of 6 chemotherapy cycles of CHOP-
21 is modelled here to reflect current UK practice, and in each chemotherapy cycle a 
patient may or may not experience an FN event.  
 
An FN event may cause chemotherapy dose delays/reductions (i.e. sub-optimal 
relative dose intensity, RDI) which may affect patient survival. (20) Post-
chemotherapy, the model uses a state transition model with a cycle length of 1 year. 
Life expectancy is estimated using NHL survival data (which is dependent on stage at 
diagnosis). Patients may die of FN during chemotherapy and from NHL or other 
causes after chemotherapy. During chemotherapy only deaths due to FN are 
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considered but post chemotherapy deaths from NHL and other causes are 
considered.  
 
One and two way sensitivity analyses were undertaken. Probabilistic sensitivity 
analyses (PSA) were run using 10,000 sets of parameters sampled independently 
from the parameter distributions. Distributions used were taken or calculated from 
published sources where available. Further details on choice of distributions are 
given in the data population section. The appropriateness of 10,000 configurations 
was tested using jack-knife techniques.(21)  
 
Data Population 
 
Calculating FN risk for patients receiving no prophylaxis 
Baseline FN risk, defined as the likelihood of having at least one FN episode over all 
cycles of chemotherapy in the absence of any G-CSF prophylaxis during treatment, 
can vary widely amongst patients depending on chemotherapy regimen, patient age, 
performance status, and other risk factors.(7) The EORTC guidelines show that 
baseline risk can vary from 11% to 78% for NHL chemotherapy regimens.(7) It has 
also been established that the risk of an initial FN episode is greatest in 
chemotherapy cycle 1, with over 50% of initial FN events occurring in the first 
cycle.(22) (23) The relative risk of an initial FN event in cycles 2 onwards compared 
with cycle 1 was calculated as 0.2 (95% CI: 0.14 – 0.25) using data from an 
observational study of 577 NHL patients receiving CHOP chemotherapy. (22) In 
addition, occurrence of an FN event indicates that a patient is at a higher risk of 
further FN events in subsequent cycles. The increased relative risk of further FN 
episodes in a patient with prior episodes was calculated as 9.09 (95% CI 6.19-13.35), 
using data from a breast cancer study which was the only source found which 
distinguished between initial and subsequent FN events by cycle.(24) Lognormal 
distributions fitted to these confidence intervals were used for these FN related 
relative risks.  
  
For high grade NHL, CHOP and R-CHOP are the most common first-line regimens.(15) 
For patients with NHL receiving CHOP chemotherapy the reported FN incidence 
ranges from 17-50%. (25) (26)  Lyman et al report a FN hospitalisation rate of 17% for 
patients receiving CHOP/R-CHOP/CNOP; patients in this study had a median age of 
63 years and 8% received G-CSF prophylaxis.(25) Three RCTs in elderly patients 
receiving CHOP reported that patients in the control arm (not receiving primary G-
CSF prophylaxis) had an FN incidence of 37%, 45% and 50% (median age 71-72 in all 
studies).(10;26;27) The base case analysis in the present study is based on a FN risk 
level of 17% and a patient age of 63 years. A secondary analysis considers a FN risk 
level of 45% for a patient age of 72 years. 
 
To inform decision-making for a broad population of patients, we modelled the cost-
effectiveness of G-CSF for a range of baseline FN risk values. Our model required the 
FN risk per cycle, which we calculated from the baseline risk using the information 
given above, and assuming 6 cycles of chemotherapy.  For example, assuming a FN 
risk of 20%, this was estimated to be a risk of 10% in cycle 1 and a risk of 2% in each 
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of cycles 2-6. If a patient had an FN episode in cycle 1, this increased the FN risk in 
each subsequent cycle to 18%. Further details on these calculations are given in a 
similar cost-effectiveness analysis for breast cancer. (13) 
 
G-CSF efficacy and duration of treatment 
A full systematic review of literature relating to G-CSF efficacy was undertaken. The 
comparative efficacy of the three G-CSFs in reducing FN risk is evaluated using meta-
analyses of trials of each G-CSF compared with no primary G-CSF prophylaxis 
(summarised in Table 1). This included all reported RCTs comparing primary G-CSF 
prophylaxis versus no primary G-CSF prophylaxis in adult solid tumour and malignant 
lymphoma patients. This work updated an existing meta-analysis by Kuderer et al 
(28) and a summary table is provided in the breast cancer cost-effectiveness 
analysis.(13) The results of the meta-analysis were used in the base-case analysis.  
 
The majority of clinical trials of filgrastim and lenograstim alongside chemotherapy 
cycles of 3-week duration used approximately 11 injections per cycle, by which point 
the neutrophil count had generally recovered.(5;29;30) Therefore we have assumed 
that 11 days’ treatment with either lenograstim or filgrastim is consistent with the 
efficacy evidence reported within the RCTs. To account for the possibility of a shorter 
duration we have also modelled the use of filgrastim/lenograstim for 6 days and 
optimistically assumed the same efficacy as for 11 days. A retrospective analysis by 
Weycker et al showed that the risk of hospitalisation for neutropenia or infection 
declined with each additional day of filgrastim use, with an odds ratio of 0.81 (95% 
CI: 0.70, 0.93). Hence our assumption is likely to overestimate efficacy in the 6 day 
arm. 
 
Mortality rates 
The probability of dying through causes other than NHL is assumed to be dependent 
on age, and is taken from Office for National Statistics data.(31) The model used NHL 
survival data which was dependent on age, sex, number of years since diagnosis and 
whether the patient had an RDI level of 85% or greater. Relative survival data from 
2000-2004 for Scotland was used because it includes survival rates at 1, 3, 5 and 10 
years, by age and sex and by year since diagnosis, and equivalent data could not be 
identified for England or Wales.(32) It is assumed that the mortality rate is constant 
in years 2 and 3, years 4 and 5, and in years 6 onwards. Mortality rates are available 
at age range midpoints and interpolation is used for ages between these points. A 
limitation of these data is that they relate to all NHL patients, not just those who 
undergo chemotherapy. It is not clear in which direction this will bias results as the 
fact that a patient is receiving chemotherapy may indicate a good performance 
status but it may also indicate advanced disease with an increased risk of mortality.  
 
A study by Kuderer et al analysed 8,871 lymphoma patients hospitalised for FN in the 
US between 1995 and 2000.(1) The mortality rate from FN for lymphoma patients 
was 8.9% (95% CI 8.3% to 9.5%) and this is used in the model.  
 
Reduced relative dose intensity (RDI) of chemotherapy due to FN 
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A high proportion of NHL patients on chemotherapy experience FN with the 
consequence of impaired chemotherapy delivery.(33) In NHL, reduced RDI is 
commonly defined as receipt of <90% of the planned chemotherapy dose intensity 
(either as a result of a reduced dose or a delay between doses).   
 
A retrospective study of 4,522 patients with aggressive NHL treated with CHOP, R-
CHOP or CNOP assessed the incidence of and risk factors for reduced RDI.(34) A 
multivariate analysis identified several independent predictors for reduced RDI, 
including age older than 60 years, advanced disease stage, poor performance status, 
and no prophylactic CSF use but found that age was no longer a significant risk factor 
in patients who received prophylactic CSF. (34)  
 
In the model it is assumed that FN is a risk factor for reduced RDI. A prospective 
observational study found the proportion of patients with RDI ≤90% was 40.8% in 
the group without FN and 70.6% in the group with FN; these rates have been used in 
the model. (33) 
 
Impact of RDI on survival 
The relationship between chemotherapy dose intensity and survival is uncertain. 
However, it is generally considered that a reduction in RDI below the optimum is 
likely to be detrimental to long-term survival from cancer.(35) In particular, in 
situations where dose-dense or dose-intense chemotherapy strategies are used 
reduction in RDI may be detrimental to survival. (7) 
 
A retrospective study of NHL patients by Bosly et al, performed a multivariate Cox 
regression analysis of factors significantly associated with overall survival in patients 
receiving CHOP-21 (N=210). (20) This found that average RDI (ARDI) ≤90 vs. >90% 
was associated with a hazard ratio (HR) for overall survival of 0.48 (95% CI 0.27, 
0.84), p-value=0.011. In this study 60 patients (29%) had ARDI ≤90% whilst 150 
persons (71%) had ARDI>90%. We note that as this is a retrospective study it may be 
confounded by the fact that patients who have their dose intensity reduced may be 
those who are more likely to die due to other factors such as older age and poorer 
performance status.   
 
The values from this study were used to estimate mortality rates for low and high 
RDI from the mean age dependent mortality rate as follows: 
 
Mean mortality rate = (probability RDI <90%)*(mortality if RDI <90%)  
+ (probability of RDI >=90%)*(mortality if RDI >=90%). 
 
Hence rearranging we get: 
Mortality if RDI <90%   = mean mortality / (29%+71%*HR), and 
Mortality if RDI >=90% = mean mortality*HR / (29%+71%*HR). 
 
As the quality of the data relating FN events to reduced RDI and reduced RDI to 
survival is of poor quality a sensitivity analysis was performed which assumes that 
RDI has no effect on survival. 
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Utility values 
Utility values which are dependent on both health state and patient age were used. 
The average population utilities, categorised by age, have been taken from Kind et 
al.(36)  Each adverse health state (FN, receiving chemotherapy for NHL, relapsed and 
disease free) is assumed to be associated with a decreased utility for the duration of 
the event. Each chemotherapy cycle is assumed to last for 3 weeks and the mean 
length of hospitalisation following an FN event is estimated to be 10.7 days (95% CI: 
10.4 to 11.0). (1)   
 
The utility value for the health state “FN” was reported as 0.33 (37) and was 
converted into a utility multiplier of 0.398 (by dividing by 0.83, the age factor for age 
55 years,(36) assuming published utility is for patients aged 55 years). The utility 
value for the health state “receiving chemotherapy for NHL” was reported as 0.63 
with a mean patient age of 72 years and was converted into a utility multiplier of 
0.84 (by dividing by 0.75, the age factor for age 72 years). (38) (36) Based on 5 year 
survival data, it was assumed that in years 1-5 post chemotherapy 41% of patients 
experience a relapse and 59% of patients are disease free. For years 5 onwards post 
chemotherapy the disease-free state utility value was assumed for all remaining 
patients. The utility multiplier for the disease-free state, 0.94, was taken from Hind 
et al 2007 and the utility value for relapse was assumed to be 0.44, the value for the 
group with age-adjusted international prognostic index of 2-3 from the Doorduijn 
study (giving a multiplier of 0.58). (39) (38) Beta distributions were used to model 
uncertainty in utility values. 
 
Valuation of Costs 
Only costs incurred during the time on chemotherapy are included in the model. The 
unit costs used within the model are detailed in Table 2. It is assumed that G-CSF 
injections are administered by a district nurse at the patient’s home. It is assumed 
that FN treatment is administered on an inpatient basis. Filgrastim and lenograstim 
were assumed to be administered as weight based doses at 5mcg/kg/day and details 
are provided in a similar cost-effectiveness analysis for breast cancer. (13) Since the 
G-CSF market in the UK is driven by competitive tenders it is common for discounts 
to be provided on list prices. Therefore various discounted prices were considered in 
a sensitivity analysis. 
 
The costs of chemotherapy are dependent on the number of chemotherapy cycles 
received. If a patient dies from an FN event during chemotherapy, no further cycles 
are given and no further costs incurred. Chemotherapy costs vary depending on the 
regimen. For simplicity the cost of CHOP is used at £1,931 per cycle.(40) Costs of 
chemotherapy have been assumed to be independent of RDI.  
 
 
RESULTS 
 
Results are presented for a baseline FN risk of 17% and a patient age of 63 years 
which corresponds to a study of patients receiving CHOP/R-CHOP/CNOP 
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chemotherapy.(41)  We calculate the incremental costs and QALYs compared with a 
strategy of no G-CSF prophylaxis. These are presented alongside the net monetary 
benefits and incremental cost effectiveness ratio (ICER) in Table 3. We observe that 
all the strategies involving the once-daily G-CSFs (filgrastim and lenograstim) are 
never optimal. The ICER for secondary prophylaxis with pegfilgrastim was £7,631 and 
for primary prophylaxis it was £27,176. The cost effectiveness acceptability curve 
(CEAC) (42) is shown in Figure 3. With a WTP threshold of £30,000 per QALY primary 
and secondary prophylaxis with pegfilgrastim each have a probability of being the 
most cost effective of 0.5. Jack-knife techniques on an example dataset of 10,000 
PSA runs showed that the confidence interval around a mean cost per QALY was 
small (less than £1,000 in all cases). 
 
We also performed an analysis which corresponds to elderly patients receiving 
CHOP. For this subgroup the analysis used an age of 72 and a FN risk level of 
45%.(10;26;27) For this subgroup the ICER for primary prophylaxis with pegfilgrastim 
was £6,903 whilst secondary prophylaxis with pegfilgrastim was cost saving. 
 
Deterministic one-way sensitivity analysis on baseline FN risk level was performed 
for a selection of scenarios and results are presented in Figure 4.  Results are highly 
sensitive to baseline FN risk. The base case analysis with a WTP threshold of £20,000 
per QALY demonstrated that for a patient with an FN risk level of 8-22% secondary 
prophylaxis with pegfilgrastim is most cost effective and for patients with higher FN 
risk levels primary prophylaxis with pegfilgrastim becomes the most cost effective. 
Using a WTP threshold of £30,000, primary prophylaxis with pegfilgrastim was cost-
effective for baseline FN risks greater than 16% and secondary at FN risk of 6-15%. 
 
The scenario analyses performed demonstrate that age at diagnosis, WTP threshold, 
effect of RDI on survival, sex, and G-CSF price all significantly affect the level of 
baseline FN risk at which G-CSF prophylaxis becomes cost effective. The scale of the 
effect these variables can have on the ICER is shown in Figure 4.  
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DISCUSSION 
 
The cost effectiveness of prophylaxis with the G-CSFs pegfilgrastim, filgrastim and 
lenograstim is estimated in patients with NHL. Our results indicated that the most 
cost-effective strategy is dependent on the estimated baseline risk of FN for an 
individual patient, the cost per QALY threshold, patient age and G-CSF price. It is 
noted that in all scenarios the most cost-effective strategy was one of primary 
pegfilgrastim, secondary pegfilgrastim or no G-CSFs and strategies involving 6/11-day 
filgrastim or lenograstim were dominated. 
 
A sensitivity analysis on age at diagnosis demonstrates that for younger age-groups 
primary prophylaxis with pegfilgrastim is more likely to be the most cost effective 
strategy. Since the G-CSF market in the UK is driven by competitive tenders it is 
common for discounts to be provided on list prices. Including the possible 
discounting of G-CSFs within the modelling also greatly reduces the FN risk threshold 
at which primary prophylaxis with pegfilgrastim is cost effective. The overall decision 
on whether to use G-CSFs will depend on the clinician’s assessment of risk factors for 
a particular patient. 
 
For a particular chemotherapy regimen, the baseline FN risk, and therefore the cost-
effectiveness of G-CSF prophylaxis, will vary for individual patients depending on 
patient risk factors such as performance status, age, etc. A clinician would be 
assumed to estimate the risk of FN for an individual patient according to factors such 
as performance status as well as the chemotherapy regimen they were receiving. As 
age increases, there will be a decrease in remaining expected QALYs but an increase 
in expected baseline FN risk which impact the cost-effectiveness in opposing 
directions 
 
The cost effectiveness analysis of G-CSF prophylaxis for breast cancer patients 
undergoing chemotherapy concluded that a WTP threshold of £30,000 primary 
prophylaxis with pegfilgrastim was cost effective for patients with an FN risk of 
greater than 29%.(13) For NHL, G-CSF prophylaxis is cost effective at a lower FN risk 
level of 16%. As NHL patients often receive treatment with chemotherapy regimens 
associated with a high risk of febrile neutropenia, it follows that G-CSF prophylaxis 
may be cost effective for a large proportion of NHL patients. 
 
This study had a number of limitations. Certain assumptions had to be made due to 
limitations in the data available. For example UK-specific data was not available for 
all parameter values so data from other countries was used. A statistical analysis 
relating patient age, performance status and chemotherapy to FN risk was not 
available but the modelling would be improved if the relationship between these 
factors was included. The availability of further data reporting FN events with details 
of chemotherapy cycle number and initial FN events would make the modelling 
more robust. For example, no NHL-specific data was identified for the increase in FN 
risk in patients having had an initial FN event, so data from a breast cancer study was 
used. The retrospective nature of the data linking RDI to survival and the lack of 
efficacy data for 6 day daily G-CSFs are also limitations. 
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A published cost-effectiveness analysis which evaluated the cost-effectiveness of 
pegfilgrastim versus 6-day filgrastim primary prophylaxis found ICERs of between 
$1,677 and $6,190 per QALY.(43) This model differed in several respects from the 
model described here: a US perspective was taken, each cycle of chemotherapy was 
not modelled separately, the risk of FN was assumed the same for secondary 
prophylaxis and no G-CSFs, and a baseline FN risk of 27.9% was used. Differences in 
the conclusions of these analyses are due to: the use of different pegfilgrastim 
efficacy values, different costs and care pathways for different countries, and 
differences between the structures of the models used. 
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TABLES AND FIGURES 
 
Figure 1: Factors affecting FN risk and survival 
 
Figure 2: Schematic of the decision analytic model 
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Figure 3: Cost Effectiveness Acceptability Curves for base case analysis 
(Base Case: CHOP chemotherapy, FN risk level 17%, age 63 years, list price GCSFs) 
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Figure 4: Sensitivity Analyses: The G-CSF strategy with highest NMB for different levels of 
baseline FN risk 
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Figure 5: Tornado diagram for primary prophylaxis with pegfilgrastim compared to 
secondary prophylaxis with pegfilgrastim   
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Table 1: Relative risk of febrile neutropenia incidence with G-CSF prophylaxis 
 
G-CSF prophylaxis Source Relative risk of FN compared with no G-CSF 
prophylaxis (95% CI), p value 
Pegfilgrastim  Vogel 2005(6), Balducci 
2007(10), Romieu 2007(44), 
Hecht 2009(45) 
0.30 (0.14 to 0.65), p=0.002 
Filgrastim (11 day) Kuderer 2007(28), del Giglio 
2008(46) 
0.57 (0.48 to 0.69), p<0.00001 
Filgrastim (6 day) Assumed same as 11 day 0.57 (0.48 to 0.69), p<0.00001 
Lenograstim (11 day) Kuderer 2007(28) 0.62 (0.44 to 0.88), p=0.007 
Lenograstim (6 day) Assumed same as 11 day 0.62 (0.44 to 0.88), p=0.007 
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Table 2: Summary of parameters used in model: deterministic values, distribution used in 
PSA, and references 
 
Variable Value Distribution Source 
Costs    
Cost of pegfilgrastim per injection £     686.24 Assumed fixed BNF(47) 
Cost of filgrastim per injection (weight based 
dose 5mcg/kg/day) 
£       98.39 Assumed fixed BNF(47) 
Cost of lenograstim per injection 
(weight based dose 5mcg/kg/day) 
£       111.83 Assumed fixed BNF(47) 
Cost of administrating a G-CSF injection £       21.00 Assumed fixed Curtis 2007(48) 
Cost of CHOP chemotherapy per cycle £  1931.00 Assumed fixed Knight et al 2004 (40) 
Cost of hospitalisation per day £     235.00 Assumed fixed Curtis 2007(48) 
Cost of IV antibiotics during hospitalisation £       47.23 Assumed fixed BNF(47) 
Cost of daily investigations (per day of 
hospitalisation) 
£         9.27 Assumed fixed Sweetenham et al 
1999(49) 
uplifted to 2007 
Cost of once-per-FN investigations (per FN) £       47.86 Assumed fixed Sweetenham et al 
1999(49) 
uplifted to 2007 
Average duration of hospitalisation for an FN 
event in days 
10.7 Normal(Mean = 10.7, Std Dev = 
0.153) 
Kuderer et al 2006(1) 
Rate used for discounting costs and QALYs 0.035  NICE reference case(18) 
    
RDI and mortality inputs    
Probability of dying from an FN event 0.089 Normal(Mean = 0.089, Std Dev = 
0.003) 
Kuderer et al 2006(1)  
Probability of low RDI for patients with no FN 40.8% Normal(Mean=0.41 StdDev=0.04), 
95% CI (0.34,0.48) 
Pettengell et al 2006 (33) 
Probability of low RDI for patients with FN 70.6% Normal(Mean=0.71 StdDev=0.06), 
95% CI (0.58,0.83) 
Pettengell et al 2006 (33) 
Hazard Ratio for survival if low RDI (<90%) 0.48 Log-normal (mean of logs=--0.7594, 
sd of logs=0.2895) 
Bosly et al 2007(20) 
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FN risk 
Relative risk of an FN event with pegfilgrastim 
primary prophylaxis vs. no G-CSF 
0.30 Log-normal (mean of logs=-1.2820, sd 
of logs=0.4709) 
meta-analysis, Vogel 
Relative risk of filgrastim 11 days compared 
with no G-CSF 
0.57 Log-normal (mean of logs=-0.4909, sd 
of logs=0.0799) 
Kuderer et al 2007(28) 
Relative risk of lenograstim compared with no 
G-CSF 
0.62 Log-normal (mean of logs=-0.4886, sd 
of logs=0.1754) 
Kuderer et al 2007(28) 
Relative risk of an FN event if patient has 
already had an FN event 
9.089 
Log-normal (mean of logs=2.1878, sd 
of logs=0.1961) 
Calculated from data in 
von Minckwitz et al 
2008(24) 
Relative risk of an FN event in cycles 2-6 
compared with cycle 1 
0.186 Log-normal (mean of logs=-1.696, sd 
of logs=0.1533) 
Calculated from data in 
Lyman et al 2003(22) 
    
Utility values and multipliers*     
NHL undergoing chemotherapy 0.63  Range 0.54-0.71 
 
Doorduijn et al 2005(38) 
NHL undergoing chemotherapy- multiplier 0.84 Beta(33.5,6.4)  95% CI 0.72-0.94 
 
 
FN event hospitalisation 0.33 
Range 0.24-0.42 
 
Brown et al 2001(50); 
Brown & Hutton 
1998(51) 
FN event hospitalisation - multiplier 0.398 Beta(30.7, 46.5) 95% CI 0.29-0.51 
  
 
Relapsed NHL 0.44  Doorduijn et al 2005 (38) 
Relapsed NHL - multiplier 0.58 Beta(53.7, 38.9)  
Years 1-5 post chemo - multiplier 0.79   
Years 5+ post chemotherapy- multiplier 0.94 Beta(3.44, 0.21) Hind et al 2007(39) 
    
*Utility multipliers are multiplied by an age-specific average utility value from Kind et al 1998(36) 
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Table 3: Probabilistic Sensitivity Analyses Results 
 
Cost (£) QALYs
 Incr. Cost 
(£) 
 Incr. 
QALYs 
 Incr NMB 
(£), 
WTP=£20
K 
 Incr NMB 
(£), 
WTP=£30
K ICER*
No GCSFs 12,214£    6.540   -           -       -          -          
Secondary prophylaxis with 
lenograstim for 11 days 12,905£    6.556   691          0.016    378-         222-         dominated
Secondary prophylaxis with 
lenograstim for 6 days 12,554£    6.556   340          0.016    27-           130         dominated
Secondary prophylaxis with 
filgrastim for 6 days 12,500£    6.558   286          0.018    71           249         dominated
Secondary prophylaxis with 
filgrastim for 11 days 12,816£    6.558   602          0.018    245-         67-           dominated
Secondary prophylaxis with 
pegfilgrastim 12,437£    6.569   223          0.029    362         654         7,631£      
Primary prophylaxis with 
lenograstim for 11 days 20,647£    6.630   8,433        0.089    6,646-       5,752-       dominated
Primary prophylaxis with 
lenograstim for 6 days 16,687£    6.630   4,473        0.089    2,686-       1,793-       dominated
Primary prophylaxis with 
filgrastim for 11 days 19,734£    6.642   7,519        0.102    5,489-       4,473-       dominated
Primary prophylaxis with 
filgrastim for 6 days 16,172£    6.642   3,958        0.102    1,927-       912-         dominated
Primary prophylaxis with 
pegfilgrastim 15,969£    6.699   3,755        0.159    571-         1,021       27,176£    
No GCSFs 13,970£    6.071   -           -       -          -          
Secondary prophylaxis with 
pegfilgrastim 13,941£    6.256   29-            0.185    3,736       5,590       155-£        
Primary prophylaxis with 
pegfilgrastim 16,284£    6.596   2,314        0.525    8,181       13,428     6,903£      
Base Case Analysis: FN risk level 17%, age 63
Second Example Analysis: Elderly patients - FN risk level 45%, age 72
* ICERs are only presented for strategies on the cost effectiveness frontier. The ICER is calculated compared to the 
next less effective strategy on the cost effectiveness frontier.  
 
  
